Phathom Pharmaceuticals (PHAT) PT Raised to $12 at Goldman Sachs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 hits record high as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Burry doubles down on Nebius short after stock surges 34% on earnings
- S&P 500 ends higher as CoreWeave results fuel AI optimism
- Home Depot CEO Ted Decker takes medical leave; two executives step in
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Phathom Pharmaceuticals Inc. (PHAT) spreader active in August 10 and November 10 calls
August 8, 2024 2:53 PM EDTPhathom Pharmaceuticals Inc. (NASDAQ: PHAT) 30-day option implied volatility is at 82; compared to its 52-week range of 55 to 180 with a focus on August 10 and November 10 call spread.
... MorePhathom Pharmaceuticals, Inc. (PHAT) Tops Q2 EPS by 7c
August 8, 2024 8:05 AM EDTPhathom Pharmaceuticals, Inc. (NASDAQ: PHAT) reported Q2 EPS of ($1.25), $0.07 better than the analyst estimate of ($1.32). Revenue for the quarter came in at $7.3 million versus the consensus estimate of $5.68 million.
For earnings history and earnings-related data on Phathom Pharmaceuticals, Inc. (PHAT) click here.
... More